- Home
- TYGO vs SPRO Comparison
TYGO vs SPRO Comparison
Compare TYGO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- SPRO
- Stock Information
- Founded
- TYGO 2007
- SPRO 2013
- Country
- TYGO United States
- SPRO United States
- Employees
- TYGO N/A
- SPRO N/A
- Industry
- TYGO Semiconductors
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- SPRO Health Care
- Exchange
- TYGO Nasdaq
- SPRO Nasdaq
- Market Cap
- TYGO 45.8M
- SPRO 45.7M
- IPO Year
- TYGO N/A
- SPRO 2017
- Fundamental
- Price
- TYGO $0.80
- SPRO $0.75
- Analyst Decision
- TYGO Buy
- SPRO Buy
- Analyst Count
- TYGO 3
- SPRO 4
- Target Price
- TYGO $3.00
- SPRO $5.00
- AVG Volume (30 Days)
- TYGO 25.6K
- SPRO 218.6K
- Earning Date
- TYGO 05-13-2025
- SPRO 05-14-2025
- Dividend Yield
- TYGO N/A
- SPRO N/A
- EPS Growth
- TYGO N/A
- SPRO N/A
- EPS
- TYGO N/A
- SPRO N/A
- Revenue
- TYGO $54,014,000.00
- SPRO $47,977,000.00
- Revenue This Year
- TYGO $61.65
- SPRO N/A
- Revenue Next Year
- TYGO $28.03
- SPRO N/A
- P/E Ratio
- TYGO N/A
- SPRO N/A
- Revenue Growth
- TYGO N/A
- SPRO N/A
- 52 Week Low
- TYGO $0.58
- SPRO $0.51
- 52 Week High
- TYGO $1.85
- SPRO $1.72
- Technical
- Relative Strength Index (RSI)
- TYGO 47.55
- SPRO 54.69
- Support Level
- TYGO $0.70
- SPRO $0.51
- Resistance Level
- TYGO $0.84
- SPRO $0.83
- Average True Range (ATR)
- TYGO 0.11
- SPRO 0.08
- MACD
- TYGO 0.00
- SPRO 0.01
- Stochastic Oscillator
- TYGO 58.54
- SPRO 76.85
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.